The BD Phoenix™ M50 instrument provides clinicians with accurate and timely identification and susceptibility results to help guide their therapy and patient management decisions.
Delivering performance, connectivity and functionality required by clinical microbiology laboratories
The BD Phoenix™ M50 instrument provides clinicians with accurate and timely identification and susceptibility results to help guide their therapy and patient management decisions.
The BD EpiCenter™ data management system interfaces with the BD Phoenix™ M50 and provides intuitive, on-demand antibiogram generation and flexible reporting options.
The BD Phoenix™ system utilizes on-panel doubling dilutions of antimicrobial concentrations for determination of MIC results.
The BD Phoenix™ M50 instrument employs a delayed growth algorithm that may defer reporting for slow-growing organisms until additional instrument readings are collected. This feature enables an accurate determination of growth or no-growth, providing additional assurance that results are accurate.
The BD Phoenix™ system provides on-panel doubling dilutions of antimicrobials and built-in detection of resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*. *Depending on BD Phoenix™ panel type and organism identification.
The BD EpiCenter™ data management system offers the BDXpert system, which implements CLSI breakpoints and SIR interpretations. BD EpiCARE™ is an optional extension of the BD EpiCenter™ system that gives users the ability to define customized rules and actions to ensure compliance for the reporting of microbiology data that may be specific to their organization.
The BD Phoenix™ M50 instrument offers a compact and stackable design (up to two instruments) that allows for increased testing volumes by doubling capacity within the same footprint.
The BD Phoenix™ AP automated inoculation preparation instrument may help to reduce sample preparation workflow burdens, reducing total hands-on time per sample by 50% compared to manual BD Phoenix™ preparation and by an average of 20% compared to selected competitive products. 1-2
* Depending on BD Phoenix™ panel type and organism identification
**BD internal studies—data on file
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.